Treatment of hair loss disorders with deuterated jak inhibitors
AssigneeConcert Pharmaceuticals, Inc.
InventorsAmanda T. Wagner, James V. Cassella, Philip B. Graham, Virginia Braman, Vinita Uttamsingh, Jana Von Hehn, Colleen E. Hamilton
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
Claims31
A method of treating a hair loss disorder in a mammalian subject, the method comprising administering to the subject an amount in the range of 4 mg to 50 mg per day, of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and 4 to 50 mg of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating a hair loss disorder in a mammalian subject, the method comprising administering to the subject twice a day about 4 mg of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating a hair loss disorder in a mammalian subject, the method comprising administering to the subject twice a day about 8 mg of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating a hair loss disorder in a mammalian subject, the method comprising administering to the subject twice per day about 12 mg of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating a hair loss disorder in a mammalian subject, the method comprising administering to the subject twice a day about 16 mg of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.